Quantcast

Latest Serotonin-norepinephrine reuptake inhibitor Stories

2009-05-07 11:38:00

STAMFORD, Conn., May 7 /PRNewswire/ -- RYZOLT(TM) (tramadol HCl extended-release tablets) is now available from Purdue Pharma L.P. for the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time. (Photo: http://www.newscom.com/cgi-bin/prnh/20090507/NY13103) RYZOLT's active ingredient, tramadol, is a centrally-acting synthetic opioid analgesic that binds to the mu -opioid receptor and also...

2009-04-20 07:00:00

NEW YORK and SAN DIEGO, April 20, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) and Cypress Bioscience, Inc. (Nasdaq: CYPB) announced today that Savella(TM) (milnacipran HCl), a selective serotonin and norepinephrine dual reuptake inhibitor approved for the management of fibromyalgia, will be shipped to wholesalers on April 24th and will be available at pharmacies beginning on April 28th. After Savella was approved by the U.S. Food and Drug Administration (FDA) on...

2009-03-06 07:00:00

NEW YORK and SAN DIEGO, March 6, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) and Cypress Bioscience, Inc. (Nasdaq: CYPB) announced today that they expect to ship Savella(TM) (milnacipran HCl), a selective serotonin and norepinephrine reuptake inhibitor for the management of fibromyalgia, to wholesalers and pharmacies by mid 2009. Savella was approved by the U. S. Food and Drug Administration (FDA) on January 14, 2009 and was originally expected to be available in...

2009-01-14 18:24:00

New treatment option for the estimated 6 million Americans living with this chronic, debilitating condition NEW YORK and SAN DIEGO, Jan. 14, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) and Cypress Bioscience, Inc. (Nasdaq: CYPB) today announced that Savella(TM) (milnacipran HCl), a selective serotonin and norepinephrine dual reuptake inhibitor, was approved by the U.S. Food and Drug Administration (FDA) for the management of fibromyalgia. Fibromyalgia is a chronic...

2009-01-13 17:55:55

The use of antidepressant medications by patients with fibromyalgia syndrome is associated with a reduction in pain, sleep disturbances and depressed mood and improvement of health-related quality of life, according to an analysis of previous studies, which is published in the January 14 issue of JAMA. Fibromyalgia syndrome (FMS), which consists of chronic widespread pain and tenderness, with other symptoms including fatigue and sleep difficulties, has an estimated prevalence of 0.5 percent...

2008-10-27 12:00:10

Eli Lilly and Company has announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a negative opinion on a Cymbalta application for the treatment of fibromyalgia. The Committee for Medicinal Products for Human Use (CHMP) received data on the use of duloxetine in the treatment of fibromyalgia in 1,411 patients in four placebo-controlled studies and 350 patients in one open-label safety study, a total of 1,761 patients in five clinical...

2008-10-24 06:00:05

INDIANAPOLIS, Oct. 24 /PRNewswire-FirstCall/ -- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a negative opinion on a Cymbalta(R) (duloxetine hydrochloride) application for the treatment of fibromyalgia. "Eli Lilly and Company and Boehringer Ingelheim are naturally disappointed by the CHMP's opinion," said James Russell, M.D., global medical director for duloxetine, Eli Lilly and Company. "We remain confident in the duloxetine...

2008-10-15 09:00:48

COLLEGEVILLE, Pa., Oct. 15 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth , today provided an update on its global strategy for desvenlafaxine for the treatment of major depressive disorder (MDD) in adults. Desvenlafaxine has already been approved for the treatment of MDD in adults in the United States, Australia and Brazil, and applications are currently pending in 22 markets. As part of its global regulatory strategy, and in consultation with the Committee for...

2008-09-26 09:00:40

Adheris, Inc., a leader in patient adherence and education programs, announced today the results of a new study that examined adherence rates among patients on SSRI/SNRI antidepressant therapy. Study results showed that patients new to antidepressant treatment and those who had restarted therapy after a lapse of 6 or more months were twice as likely to discontinue therapy in the first 30 days of treatment versus patients previously dispensed an antidepressant. According to lead author...

2008-09-22 15:00:53

MONTCLAIR, N.J., Sept. 22 /PRNewswire/ -- The American Society of Pain Educators (ASPE) recently launched, the second of a three-part Webcast series: Is Your Persistent Chronic Pain Weighing You Down? at http://www.painawareness.org/. This Webcast addresses the importance of proper weight control in managing chronic pain. WHO: -- Inspirational testimony from Olympic Gold Medalist and chronic pain sufferer Nikki Stone. -- Practical pain management tips from Dr. Warren A. Katz, Clinical...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'